The Meshorer lab is studying chromatin and epigenetics in embryonic and neuronal stem cells and reprogramming and are using human pluripotent stem cells to model human neurodegenerative diseases.
Chromatin plasticity in embryonic stem (ES) cells and in ES cell differentiation
Using endogenously-labeled fluorescent libraries in mouse embryonic stem cells which we generated, we can visualize differentiation events, nuclear body dynamics, protein binding kinetics, etc. and screen for pluripotency and differentiation relevant factors, in living cells.
Identification and characterization of stem cell chromatin proteins
Using a biochemical assay ("D-CAP: differential chromatin associated proteins"), which we developed (Alajem et al., Cell Rep., 2015), we are analyzing the differential composition of chromatin proteins in different stages of stem cell differentiation in order to identify stem cell specific chromatin proteins. Once identified, we study their role in stem cell maintenance using a variety of molecular, microscopic and biochemical methods.
Using human pluripotent stem cells to model neurodegenerative diseases
Here we are using human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs) to model neurodegenerative diseases. We are studying poly-glutamine (PolyQ) diseases including Huntington's disease (HD) and Machado Joseph disease (MJD), as well as Parkinson's disease (PD).
In our ERC project, we aim to understand chromatin plasticity and the function of non-polyadenylated transcription in pluripotency. We are combining biochemistry, single cell advanced imaging assays and high throughput technologies to study chromatin and transcription at a genome-wide scale in ES cells and during differentiation and reprogramming, as well as decipher the function of candidate chromatin proteins and candidate non-polyadenylated transcripts in pluripotency.
Stem cell epigenetics (including the development of antibody microarrays)
In this project, we aim to analyze the entire epigenetic landscape in the various stages of stem cell differentiation. In collaboration with Yoav Soen (Weizmann Institute) we began to develop specialized antibody microarrays for all known histone modifications. In the future these antibody arrays will be used for a variety of systems, from analysis of different cell types to screening cancer patients.
Gil Ast, Tel-Aviv University
Gustavo Mostoslavsky, Boston University
Karsten Rippe, DKFZ
Paola Scaffidi, London Research Institute
Newman Sze, Nanyang Technological University, Singapore
Takumi Takizawa, Gunma University, Japan